![Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy - Journal of the Neurological Sciences Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy - Journal of the Neurological Sciences](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/21edf5fd-7f14-4597-8875-2e870507a603/gr1_lrg.jpg)
Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy - Journal of the Neurological Sciences
More than Just an Immunosuppressant: The Emerging Role of FTY720 as a Novel Inducer of ROS and Apoptosis
![IJMS | Free Full-Text | Reviewing the Significance of Blood–Brain Barrier Disruption in Multiple Sclerosis Pathology and Treatment | HTML IJMS | Free Full-Text | Reviewing the Significance of Blood–Brain Barrier Disruption in Multiple Sclerosis Pathology and Treatment | HTML](https://www.mdpi.com/ijms/ijms-22-08370/article_deploy/html/images/ijms-22-08370-g004.png)
IJMS | Free Full-Text | Reviewing the Significance of Blood–Brain Barrier Disruption in Multiple Sclerosis Pathology and Treatment | HTML
![From Natural Product to the First Oral Treatment for Multiple Sclerosis: The Discovery of FTY720 (Gilenya™)? - ScienceDirect From Natural Product to the First Oral Treatment for Multiple Sclerosis: The Discovery of FTY720 (Gilenya™)? - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S136759311630028X-fx1.jpg)
From Natural Product to the First Oral Treatment for Multiple Sclerosis: The Discovery of FTY720 (Gilenya™)? - ScienceDirect
![Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis | Nature Reviews Drug Discovery Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis | Nature Reviews Drug Discovery](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fnrd3248/MediaObjects/41573_2010_Article_BFnrd3248_Fig1_HTML.jpg)
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis | Nature Reviews Drug Discovery
![IJMS | Free Full-Text | The First Dose of Fingolimod Affects Circulating Extracellular Vesicles in Multiple Sclerosis Patients | HTML IJMS | Free Full-Text | The First Dose of Fingolimod Affects Circulating Extracellular Vesicles in Multiple Sclerosis Patients | HTML](https://www.mdpi.com/ijms/ijms-19-02448/article_deploy/html/images/ijms-19-02448-g007.png)
IJMS | Free Full-Text | The First Dose of Fingolimod Affects Circulating Extracellular Vesicles in Multiple Sclerosis Patients | HTML
![Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications - ScienceDirect Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0002870314004141-gr2.jpg)
Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications - ScienceDirect
![The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis | SpringerLink The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40263-015-0297-0/MediaObjects/40263_2015_297_Fig5_HTML.gif)
The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis | SpringerLink
![Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications - ScienceDirect Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0002870314004141-gr1.jpg)
Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications - ScienceDirect
![A Mechanistically Novel, First Oral Therapy for Multiple Sclerosis: The Development of Fingolimod (FTY720, Gilenya) - Jerold Chun - Discovery Medicine A Mechanistically Novel, First Oral Therapy for Multiple Sclerosis: The Development of Fingolimod (FTY720, Gilenya) - Jerold Chun - Discovery Medicine](https://www.discoverymedicine.com/Jerold-Chun/files/2011/09/discovery_medicine_no_64_volker_brinkmann_figure_1.png)
A Mechanistically Novel, First Oral Therapy for Multiple Sclerosis: The Development of Fingolimod (FTY720, Gilenya) - Jerold Chun - Discovery Medicine
![Mechanism of action of s1p receptor modulators in multiple sclerosis: The double requirement - ScienceDirect Mechanism of action of s1p receptor modulators in multiple sclerosis: The double requirement - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0035378718304995-gr1.jpg)
Mechanism of action of s1p receptor modulators in multiple sclerosis: The double requirement - ScienceDirect
![Frontiers | Fingolimod for the treatment of neurological diseases—state of play and future perspectives | Cellular Neuroscience Frontiers | Fingolimod for the treatment of neurological diseases—state of play and future perspectives | Cellular Neuroscience](https://www.frontiersin.org/files/Articles/112957/fncel-08-00283-HTML/image_m/fncel-08-00283-g004.jpg)